---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-006015"
form_type: "8-K"
ticker: "OCUL"
cik: "0001393434"
company_name: "OCULAR THERAPEUTIX, INC"
filed_at: "2026-01-23T23:59:59+00:00"
generated_at: "2026-05-16T08:22:15.579949+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Ocular Therapeutix CFO Donald Notman takes temporary medical leave; Jason Robins appointed interim CFO

## Summary
- Effective Jan 20, 2026, CFO/COO Donald Notman on temporary leave; Jason Robins named interim CFO and principal financial/accounting officer.
- Robins granted option to purchase 33,000 shares at $11.45/share, vesting monthly over four years.
- Robins, age 49, was SVP Finance since Jan 2025; previously VP Finance at Fusion Pharmaceuticals (acquired by AstraZeneca).
- No family relationships or related party transactions with Robins; standard indemnification agreement executed.

## SEC filing metadata
- accession: 0001104659-26-006015
- form_type: 8-K
- ticker: OCUL
- cik: 0001393434
- company_name: OCULAR THERAPEUTIX, INC
- filed_at: 2026-01-23T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1393434/000110465926006015/0001104659-26-006015-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1393434/000110465926006015/tm263902d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-006015
- JSON: https://secwatch.observer/filing/0001104659-26-006015.json
- Plain text: https://secwatch.observer/filing/0001104659-26-006015.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.